328 related articles for article (PubMed ID: 19169923)
1. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.
Ray R; Tyndale RF; Lerman C
J Neurogenet; 2009; 23(3):252-61. PubMed ID: 19169923
[TBL] [Abstract][Full Text] [Related]
2. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.
Cox LS; Faseru B; Mayo MS; Krebill R; Snow TS; Bronars CA; Nollen NL; Choi WS; Okuyemi KS; Salzman GA; Benowitz NL; Tyndale RF; Ahluwalia JS
Trials; 2011 Jan; 12():22. PubMed ID: 21266057
[TBL] [Abstract][Full Text] [Related]
3. Tobacco addiction and pharmacogenetics of nicotine metabolism.
Swan GE; Lessov-Schlaggar CN
J Neurogenet; 2009; 23(3):262-71. PubMed ID: 19152209
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI.
Tang DW; Hello B; Mroziewicz M; Fellows LK; Tyndale RF; Dagher A
Neuroimage; 2012 May; 60(4):2136-43. PubMed ID: 22342802
[TBL] [Abstract][Full Text] [Related]
5. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
Malaiyandi V; Sellers EM; Tyndale RF
Clin Pharmacol Ther; 2005 Mar; 77(3):145-58. PubMed ID: 15735609
[TBL] [Abstract][Full Text] [Related]
6. Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6?
Verde Z; Santiago C; Rodríguez González-Moro JM; de Lucas Ramos P; López Martín S; Bandrés F; Lucia A; Gómez-Gallego F
Pharmacopsychiatry; 2014 Jan; 47(1):33-6. PubMed ID: 24127329
[TBL] [Abstract][Full Text] [Related]
7. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
[TBL] [Abstract][Full Text] [Related]
8. Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers.
Chenoweth MJ; Sylvestre MP; Contreras G; Novalen M; O'Loughlin J; Tyndale RF
Drug Alcohol Depend; 2016 Jan; 158():139-46. PubMed ID: 26644138
[TBL] [Abstract][Full Text] [Related]
9. An association of CYP2A6 genotype and smoking topography.
Strasser AA; Malaiyandi V; Hoffmann E; Tyndale RF; Lerman C
Nicotine Tob Res; 2007 Apr; 9(4):511-8. PubMed ID: 17454707
[TBL] [Abstract][Full Text] [Related]
10. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation.
Kubota T; Nakajima-Taniguchi C; Fukuda T; Funamoto M; Maeda M; Tange E; Ueki R; Kawashima K; Hara H; Fujio Y; Azuma J
Pharmacogenomics J; 2006; 6(2):115-9. PubMed ID: 16402086
[TBL] [Abstract][Full Text] [Related]
11. 'Smoking genes': a genetic association study.
Verde Z; Santiago C; Rodríguez González-Moro JM; de Lucas Ramos P; López Martín S; Bandrés F; Lucia A; Gómez-Gallego F
PLoS One; 2011; 6(10):e26668. PubMed ID: 22046326
[TBL] [Abstract][Full Text] [Related]
12. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Schoedel KA; Hoffmann EB; Rao Y; Sellers EM; Tyndale RF
Pharmacogenetics; 2004 Sep; 14(9):615-26. PubMed ID: 15475735
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).
Chen LS; Bloom AJ; Baker TB; Smith SS; Piper ME; Martinez M; Saccone N; Hatsukami D; Goate A; Bierut L
Addiction; 2014 Jan; 109(1):128-137. PubMed ID: 24033696
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2A6 Genetic Variation, Nicotine Dependence Severity, and Treatment on Smoking Cessation Success.
Chenoweth MJ; Lerman C; Knight J; Tyndale RF
Nicotine Tob Res; 2023 May; 25(6):1207-1211. PubMed ID: 36789481
[TBL] [Abstract][Full Text] [Related]
15. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6.
Bloom AJ; Harari O; Martinez M; Madden PA; Martin NG; Montgomery GW; Rice JP; Murphy SE; Bierut LJ; Goate A
Hum Mol Genet; 2012 Jul; 21(13):3050-62. PubMed ID: 22451501
[TBL] [Abstract][Full Text] [Related]
16. Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.
Murphy SE
Chem Res Toxicol; 2017 Jan; 30(1):410-419. PubMed ID: 28092945
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Benowitz NL
Clin Pharmacol Ther; 2008 Apr; 83(4):531-41. PubMed ID: 18305452
[TBL] [Abstract][Full Text] [Related]
18. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
[TBL] [Abstract][Full Text] [Related]
19. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
Ho MK; Mwenifumbo JC; Al Koudsi N; Okuyemi KS; Ahluwalia JS; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2009 Jun; 85(6):635-43. PubMed ID: 19279561
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.
Malaiyandi V; Lerman C; Benowitz NL; Jepson C; Patterson F; Tyndale RF
Mol Psychiatry; 2006 Apr; 11(4):400-9. PubMed ID: 16402128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
